TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04344483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine and 1:100,000 Adrenaline
Description: Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
Study: NCT02940756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine
Description: Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinine-piperaquine
Description: Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to \<7 kg, one tablet once daily for those weighing 7 to \<13 kg, and two tablets once daily for those weighing 13 to \<24 kg, for three days.
Study: NCT00902772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: mg, oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: mg, oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: mg, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: mg, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: mg, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: mg, oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04642638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 was administered ID on Day 0 and Day 28.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
Study: NCT01387308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 50 mg x 2, single dose
Study: NCT04005105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive management
Description: Management based on premorbid MAP and MPP
Study: NCT04642638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
Study: NCT00298428

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood samples
Description: blood samples before percutaneous coronary intervention (PCI) and at 4 months
Study: NCT04046874

Intervention type: DRUG
Group type: OTHER
Intervention: Usual Care
Description: Pain Medication, imaging, referrals to other health services, other health care appointments

Intervention type: OTHER
Group type: OTHER
Intervention: SPLIT Stratified Model of Care
Description: Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
Study: NCT01782989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORACEA®
Description: ORACEA® (40mg doxycycline) capsule daily for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily for 24 months
Study: NCT04464304

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Smartphone
Description: Patients will participate in a similar game to the VR cohort, but will use a smartphone device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (Oculus Quest)
Description: Patients will participate in a game using VR.
Study: NCT02443181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: Implementation of closed loop DBS for essential tremor
Study: NCT02633384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol

Intervention type: OTHER
Group type: OTHER
Intervention: Lipofundin
Description: Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
Study: NCT01360359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization
Description: 3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk Motion and Fitness
Description: 3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises
Study: NCT03137147

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention for Sleep and Pain in Youth
Description: See arm description.
Study: NCT02997358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 75 mg/m² Day 1 of each 3-weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m² Day 1 of each 3-weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: 150 μg/m²/day s.c From day 3 to day 9
Study: NCT01707602

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INTANZA® 15
Description: intradermal vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip®
Description: Intramuscular vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTANZA® 15 T
Description: transcutaneous vaccination
Study: NCT00415961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoStar Paclitaxel Drug-Eluting Coronary Stent System
Description: CoStar Paclitaxel Drug-Eluting Coronary Stent System
Study: NCT02629965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Study: NCT03343977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel 50mg/m2
Description: 50 mg/m2 of docetaxel will be given on day 1 every 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel 75mg/m2
Description: 75 mg/m2 of docetaxel will be given on day 1 every 21 days
Study: NCT01726478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5 units Oxytocin
Description: Administration of 2.5 units of oxytocin after clamping of umbilical cord

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 units Oxytocin
Description: Administration of 10 units of oxytocin after clamping of umbilical cord
Study: NCT02390219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study: NCT00667433

Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir + Truvada
Description: Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
Study: NCT05529719

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Pilates Exercises
Description: Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
Study: NCT02060552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Description: oral administration of IL-1βinhibitory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
Study: NCT04068571

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-PUSH
Description: Innovative partnership for universal and sustainable healthcare
Study: NCT02348970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONIRIS®
Description: sleeping test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TALI
Description: sleeping test
Study: NCT01241162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine with adjuvant
Description: Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination
Study: NCT03171506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that \~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AND diet
Description: Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
Study: NCT01027637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 mm vessel clips
Description: evenly placed vessel clips placed at surgery and tracked by ultrasound
Study: NCT02169661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burger and Beetroot Study
Description: 50% fat, 10% beetroot extract
Study: NCT04322227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foliglurax 10 mg (treatment A)
Description: Foliglurax 10 mg, (BID) capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foliglurax 10 mg (treatment A)
Description: Foliglurax 10 mg, (BID) capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foliglurax 30 mg (treatment B)
Description: Foliglurax 30 mg, BID capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foliglurax 30 mg (treatment B)
Description: Foliglurax 30 mg, BID capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (treatment C)
Description: Placebo, BID capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (treatment C)
Description: Placebo, BID capsules, orally
Study: NCT00796211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-197
Description: CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-197
Description: CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: 0.1% nortriptyline HCl topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: 0.005% calcipotriol topical cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle of CRx-197 topical cream (placebo)
Study: NCT02809534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study: NCT00333333

Intervention type: PROCEDURE
Intervention: Cord blood
Description: Cord blood will be obtained at the time of delivery.

Intervention type: PROCEDURE
Intervention: Cord blood
Description: Cord blood will be obtained at the time of delivery.
Study: NCT01588587

Intervention type: DRUG
Intervention: Sitagliptin
Description: The dosage, frequency and duration for each sitagliptin are variant.
Study: NCT01731444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Study: NCT01588587

Intervention type: DRUG
Intervention: Alogliptin
Description: The dosage, frequency and duration for each alogliptin are variant.

Intervention type: DRUG
Intervention: Vildagliptin
Description: The dosage, frequency and duration for each vildagliptin are variant.
Study: NCT02107937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa with Standard of Care
Description: DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa sequentially chemotherapy
Description: DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
Study: NCT03577652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor, 90mg, 90mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor, 90mg, 90mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor, 90mg, 90mg twice daily
Study: NCT04393155

Intervention type: OTHER
Intervention: COVID-19+ observational
Description: This is observational -- there is no intervention
Study: NCT02458898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Text Message Reminders
Description: 45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
Study: NCT01425931

Intervention type: PROCEDURE
Intervention: Heart Lung machine
Description: measurement of microcirculation with O2C device
Study: NCT01284244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uresta pessary
Description: Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Silastic ring
Description: The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
Study: NCT02631044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel) single-dose schedule
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel) 2-dose schedule
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
Study: NCT03861390

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60 mg Prednisone
Description: Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
Study: NCT04016597

Intervention type: DEVICE
Intervention: Jaeger Masterscreen TM
Description: Single-breath nitric oxide lung diffusing capacity

Intervention type: DEVICE
Intervention: HypAir Medisoft
Description: Single-breath nitric oxide lung diffusing capacity
Study: NCT03861390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg Prednisone
Description: Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
Study: NCT00827034

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon
Description: B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets